Adjuvant Pembrolizumab (NSCLC), Elacestrant, & Pirtobrutinib
OncoPharm
00:00
Elacestrant Approval for ESR1-Mutant Breast Cancer
John announces FDA approval of elacestrant for ER-positive, HER2-negative ESR1-mutant metastatic breast cancer after endocrine therapy, from the EMERALD trial.
Play episode from 08:09
Transcript
